Trial reportPharmacogenomics2017
CYP2D6 pharmacogenetic and oxycodone pharmacokinetic association study in pediatric surgical patients.
Trial report in Pharmacogenomics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 48 citations in OpenAlex.
- Pharmacogenetic Guided Opioid Therapy Improves Chronic Pain Outcomes and Comorbid Mental Health: A Randomized, Double-Blind, Controlled Study.International journal of molecular sciences · 2023Trial
- CYP2D6 phenotype and post-surgical pain control with hydrocodone and oxycodone.Frontiers in pharmacology · 2026Article
- Opioid Use in Cancer Pain Management: Navigating the Line Between Relief and Addiction.International journal of molecular sciences · 2025Review
- Personalized anesthesia and precision medicine: a comprehensive review of genetic factors, artificial intelligence, and patient-specific factors.Frontiers in medicine · 2024Review
- Effects of pharmacogenetic profiles on pediatric pain relief and adverse events with ibuprofen and oxycodone.Pain reports · 2023Article
- Association ofAnnals of translational medicine · 2022Article
- The Role of Pharmacogenomics in Opioid Prescribing.Current treatment options in oncology · 2022Review
- Pharmacogenetic Gene-Drug Associations in Pediatric Burn and Surgery Patients.Journal of burn care & research : official publication of the American Burn Association · 2022Article
- Opioids and Vitamin C: Known Interactions and Potential for Redox-Signaling Crosstalk.Antioxidants (Basel, Switzerland) · 2022Review
- Pharmacogenomics of Opioid Treatment for Pain Management.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Opioid Analgesic Prescription in French Children: A National Population-Based Study.International journal of environmental research and public health · 2021Article
- Racial differences in opioid withdrawal syndrome among neonates with intrauterine opioid exposure.Pediatric research · 2021Observational
- A Narrative Review on Perioperative Pain Management Strategies in Enhanced Recovery Pathways-The Past, Present and Future.Journal of clinical medicine · 2021Review
- Pharmacogenomics of oxycodone: a narrative literature review.Pharmacogenomics · 2021Review
- Opioids: A Review of Pharmacokinetics and Pharmacodynamics in Neonates, Infants, and Children.European journal of drug metabolism and pharmacokinetics · 2019Review
- Updated Clinical Pharmacokinetics and Pharmacodynamics of Oxycodone.Clinical pharmacokinetics · 2019Review
- PharmGKB summary: oxycodone pathway, pharmacokinetics.Pharmacogenetics and genomics · 2018Article
- Clinical Pharmacogenetics of Cytochrome P450-Associated Drugs in Children.Journal of personalized medicine · 2017Article
- The use of oral opioids to control children's pain in the post-codeine era.Paediatrics & child healthReview
- Les opioïdes par voie orale en remplacement de la codéine pour contrôler la douleur chez les enfants.Paediatrics & child healthReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 1 country.
Funding
Abstract
aimOxycodone is partly metabolized to the active metabolite oxymorphone by hepatic CYP2D6 in the liver. Significant genetic variability in CYP2D6 activity affects oxymorphone formation. This study aimed to associate CYP2D6 genotype and oxycodone's metabolism.
methods30 children were administered oral oxycodone postoperatively. Plasma levels of oxycodone and oxymorphone, and CYP2D6 genotype were analyzed. CYP2D6 genotype and oxycodone metabolism phenotype were determined based on CYP2D6 total activity score (TAS) and metabolism phenotype: poor metabolizer (PM), intermediate metabolizer (IM), extensive metabolizer (EM) or ultrarapid metabolizer (UM).
resultsCompared with PM/IM subjects, significantly greater oxymorphone exposure was seen in EM subjects (p = 0.02 for C
conclusionCYP2D6 phenotypes explain metabolism of oxycodone in children, and oxymorphone exposure is higher in CYP2D6 EM phenotype. Further studies are needed to predict the occurrence of adverse event and tailor oxycodone dose for a specific CYP2D6 phenotype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.